Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
a) Cerebral palsy or gross motor disability · preterm infants prior to extubation
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
b) Developmental delay at 18 to 24 months · preterm infants prior to extubation
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Failed extubation · preterm infants prior to extubation
Methylxanthine probably leads to lower failed extubation compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants prior to extubation
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
a) Cerebral palsy or gross motor disability · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
b) Developmental delay at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Any apneic episodes · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).
1 finding from 1 review
Failed apnea reduction · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower failed apnea reduction compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with or at risk for apnea of prematurity
High‐dose showed no clear difference in all‐cause mortality prior to hospital discharge compared with standard‐dose strategies (low certainty).
3 findings from 1 review
RR 0.86 [0.53, 1.38]
5 studies · 723 participants
Low
RR 0.75 [0.4, 1.4]
3 studies · 333 participants
Very low
RR 0.75 [0.25, 2.3]
1 study · 238 participants
Very low
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes major neurodevelopmental disability in children aged 3 to 5 years CA compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · preterm infants at risk for apnea
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review